Skip to main content

ASCO: Maintenance Lurbinectedin + Atezolizumab Enhances Survival in Lung Cancer

Medically reviewed by Carmen Pope, BPharm. Last updated on May 27, 2025.

via HealthDay

TUESDAY, May 27, 2025 -- Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell lung cancer (ES-SCLC) live longer versus maintenance therapy with atezolizumab alone, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.

Luis G. Paz Ares, M.D., Ph.D., from the Universidad Complutense and Ciberonc in Madrid, and colleagues assessed outcomes for 660 treatment-naive patients with ES-SCLC treated with standard induction therapy (atezo, carboplatin, and etoposide) for four 21-day cycles (q3w). Patients without disease progression were then randomly assigned to either maintenance treatment q3w with lurbi (3.2 mg/m2; with granulocyte colony-stimulating factor prophylaxis) + atezo (1,200 mg; 242 patients) or atezo alone (241 patients) until disease progression, unacceptable toxicity, or withdrawal.

The researchers report that at a median 15 months of follow-up, progression-free survival by an independent review facility was significantly improved with lurbi + atezo versus atezo alone (stratified hazard ratio, 0.54). Additionally, a significant benefit in overall survival was seen with lurbi + atezo versus atezo alone (stratified hazard ratio, 0.73). Median maintenance treatment duration was 4.1 months with lurbi and 4.2 months with atezo in the lurbi + atezo group, and 2.1 months with atezo alone. Treatment-related adverse events occurred in 83.5 percent of participants in the lurbi + atezo group versus 40.0 percent of patients in the atezo-only group. Adverse events led to treatment discontinuation in 6.2 and 3.3 percent of participants, respectively.

"This outcome represents a major milestone and could provide a much-needed option for advancing the treatment of this aggressive disease," Ares said in a statement.

Several authors disclosed financial ties to pharmaceutical companies, including Jazz Pharmaceuticals, which manufactures lurbinectedin, and Genentech, which manufactures atezolizumab and funded the study.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Lung Cancer Screening Beneficial to Age 80 for Candidates Fit for Surgery

FRIDAY, Sept. 12, 2025 -- People aged 75 to 80 years at last screen who are diagnosed with screen-detected lung cancer (LC) have lower overall survival, but those undergoing...

Increased Intake of Ultraprocessed Food Raises Lung Cancer Risk

THURSDAY, July 31, 2025 -- Higher consumption of ultraprocessed foods (UPF) is associated with increased risk of lung cancer, according to a study published online July 29 in...

Lung Cancer Screening Adherence Rates Decline Annually After Baseline Screening

THURSDAY, March 20, 2025 -- Screening adherence is associated with increased overall and early-stage lung cancer detection rates among individuals undergoing lung cancer screening...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.